Novo's Wegovy has lost market share to Eli Lilly's Zepbound, and a new head-to-head study found that Zepbound patients lost ...

Under a mutual agreement with the board of directors, longtime Novo Nordisk CEO Lars Fruergaard Jørgensen—who recently ...

Novo Nordisk (NVO) stock in focus as the company promotes FDA-approved Wegovy as a ban for makers of compounding versions ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

As its obesity medication Wegovy loses a sizable portion of the market to Eli Lilly and Company (NYSE:LLY)’s competing ...

ClearBridge Investments, an investment management company, released its “ClearBridge Large Cap Value Strategy” first quarter ...

Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

Novo has a strong balance sheet and ended 2024 with about DKK 26 billion in cash and marketable securities and DKK 103 billion of debt (following the acquisition of Catalent manufacturing sites in ...

Obesity medications in development could improve accessibility and affordability, according to a presenter at Obesity ...

Investing.com -- S&P Global Ratings has upgraded the Denmark-based pharmaceutical company Novo Nordisk (NYSE: NVO) A/S to ’AA’ from ’AA-’ due to its sustainable strong ongoing growth prospects. The ...

Novo Nordisk announced on Friday morning that its CEO Lars Fruergaard Jørgensen is stepping down after leading the company for eight years. In a release announcing the decision, the Danish pharma ...

As Lars Fruergaard Jørgensen steps, Novo Nordisk seeks new leadership while production hurdles impact the competitive ...